Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.

Objectives: Nivolumab is approved as adjuvant therapy for resected stage III/IV melanoma based on the phase 3 CheckMate 238 trial. This analysis compared outcomes from CheckMate 238 with those from the real-world Flatiron Health electronic health record-derived de-identified database in patients with resected stage III melanoma (per AJCC-8) treated with adjuvant nivolumab.

Materials: Outcomes included baseline characteristics, overall survival (OS) in the CheckMate 238 cohort (randomization until death or last known alive), and real-world overall survival (rwOS) in the Flatiron Health cohort (nivolumab initiation until death or data cutoff).

Older adults' understanding of hypothetical community pharmacy quality report cards.

Background: Quality ratings for health plans and health services have become increasingly available to patients.

Objective: We sought to explore older adults' understanding of hypothetical community pharmacy report cards and the information they valued on the report card.

Methods: We recruited participants aged 50 years or older to complete a 59-question telephone survey.